The DOI matches its Crossref record; 288 of the 288 references it cites were found in a registry or an index.
Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies
Open accessAbstract
In tumors, Cancer-Associated Fibroblasts (CAFs) constitute the most prominent component of the tumor microenvironment (TME). CAFs are heterogeneous and composed of different CAF subsets exerting distinct functions in tumors. Specific CAF subpopulations actively influence various aspects of tumor growth, including cancer cell survival and proliferation, angiogenesis, extracellular matrix (ECM) remodeling, metastatic spread and chemoresistance. During the past decade, some CAF subsets have also been shown to modulate anti-tumor immune response. Indeed, they can increase the content in regulatory T lymphocytes and inhibit the activity of effector and cytotoxic immune cells. These functions are mainly controlled by their constitutive secretion of cytokines, chemokines, growth factors and ECM proteins, either directly in the surrounding extracellular space or through micro-vesicles. Some CAFs also express key regulators of immune checkpoints. The different roles played by CAFs, both as immunosuppressor or as physical support for tumor cell progression, set them as promising targets for anti-tumor therapies. In this review, we describe the main current knowledge on CAFs heterogeneity and immunosuppressive microenvironment, as well as their potential therapeutic implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–288 of 288
Qin, X., Yan, M., Wang, X., Xu, Q., Wang, X., Zhu, X., Shi, J., Li, Z., Zhang, J., & Chen, W. (2018) · Theranostics · doi:10.7150/thno.22182 · Cited by 172
Integrins, CAFs and Mechanical Forces in the Progression of Cancer
Jang, I., & Beningo, K. (2019) · Cancers · doi:10.3390/cancers11050721 · Cited by 170
Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma
Takahashi, H., Sakakura, K., Kawabata‐Iwakawa, R., Rokudai, S., Toyoda, M., Nishiyama, M., & Chikamatsu, K. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1742-0 · Cited by 166
Duperret, E. K., Trautz, A., Ammons, D. T., Perales‐Puchalt, A., Wise, M. C., Yan, J., Reed, C., & Weiner, D. B. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2033 · Cited by 165
Stromal integrin α11 regulates PDGFRβ signaling and promotes breast cancer progression
Primac, I., Maquoi, E., Blacher, S., Heljäsvaara, R., Deun, J. V., Smeland, H. Y., Canale, A., Louis, T., Stuhr, L. E. B., Sounni, N. E., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125890 · Cited by 165
The perivascular origin of pathological fibroblasts
Di Carlo, S. E., & Peduto, L. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93558 · Cited by 164
Denton, A. E., Roberts, E. W., Linterman, M. A., & Fearon, D. T. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412910111 · Cited by 164
Ino, Y., Yamazaki–Itoh, R., Oguro, S., Shimada, K., Kosuge, T., Závada, J., Kanai, Y., & Hiraoka, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055146 · Cited by 160
Fullár, A., Dudás, J., Oláh, L., Hollósi, P., Papp, Z., Sobel, G., Karászi, K., Paku, S., Baghy, K., & Kovalszky, I. (2015) · BMC Cancer · doi:10.1186/s12885-015-1272-3 · Cited by 160
Fibroblasts Fuel Immune Escape in the Tumor Microenvironment
De Jaeghere, E. A., Denys, H. G., & De Wever, O. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.09.009 · Cited by 160
Impact of Epithelial–Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ
Strell, C., Paulsson, J., Jin, S.-B., Tobin, N. P., Mezheyeuski, A., Roswall, P., Mutgan, C., Mitsios, N., Johansson, H., Wickberg, S. M., et al. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy234 · Cited by 158
Patel, R. A., Forinash, K. D., Pireddu, R., Sun, Y. H., Sun, N., Martin, M. P., Schönbrunn, E., Lawrence, N. J., & Sebti, S. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0954 · Cited by 157
Global Hypomethylation of Genomic DNA in Cancer-Associated Myofibroblasts
Jiang, L., Gonda, T. A., Gamble, M. V., Salas, M. C., Seshan, V., Tu, S., Twaddell, W. S., Hegyi, P. J., Lázár, G., Steele, I. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1319 · Cited by 156
Ecker, B. L., Kaur, A., Douglass, S. M., Webster, M. R., Almeida, F. V., Marino, G. E., Sinnamon, A. J., Neuwirth, M. G., Alicea, G. M., Ndoye, A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0168 · Cited by 153
Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer
Goehrig, D., Nigri, J., Samain, R., Wu, Z., Cappello, P., Gabiane, G., Zhang, X., Zhao, Y., Kim, I.-S., Chanal, M., et al. (2018) · Gut · doi:10.1136/gutjnl-2018-317570 · Cited by 151
Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling
Cruz‐Bermúdez, A., Briviesca, R. L., Vicente-Blanco, R. J., García‐Grande, A., Coronado, M. J., Laine-Menéndez, S., Alfaro, C., Sánchez, J. C., Franco, F., Calvo, V., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.10.450 · Cited by 150
Yeo, I. J., Lee, C., Han, S., Yun, J., & Hong, J. T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107394 · Cited by 147
Hyaluronan, Cancer-Associated Fibroblasts and the Tumor Microenvironment in Malignant Progression
McCarthy, J. B., El‐Ashry, D., & Turley, E. A. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00048 · Cited by 145
Fibroblast Activation Protein-α
Kelly, T. J., Huang, Y., Simms, A. E., & Mazur, A. (2012) · International review of cytology · doi:10.1016/b978-0-12-394308-8.00003-0 · Cited by 144
Carapuça, E., Gemenetzidis, E., Feig, C., Bapiro, T. E., Williams, M. D., Wilson, A. S., Delvecchio, F. R., Arumugam, P., Grose, R. P., Lemoine, N. R., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4727 · Cited by 144
Cancer-associated fibroblasts promote angiogenesis in gastric cancer through galectin-1 expression
Tang, D., Gao, J., Wang, S., Ye, N., Chong, Y., Huang, Y., Wang, J., Li, B., Yin, W., & Wang, D. (2016) · Tumor Biology · doi:10.1007/s13277-015-3942-9 · Cited by 138 · cited 1×
“CAFs also produce galectins, known as S-type lectins, carbohydrate-binding proteins that mediate cell-cell or cell-ECM communications [143, 144].”
Ziani, L., Safta, T. B., Gourbeix, J., Cavalcanti, A., Robert, C., Favre, G., Chouaïb, S., & Thiery, J. (2017) · Oncotarget · doi:10.18632/oncotarget.15540 · Cited by 137
Mechanisms of tumor escape from immune system: Role of mesenchymal stromal cells
Poggi, A. D., Musso, A., Dapino, I., & Zocchi, M. R. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.03.001 · Cited by 135
Popov, A., Abdullah, Z., Wickenhauser, C., Saric, T., Driesen, J., Hanisch, F.-G., Domann, E., Raven, E. L., Dehus, O., Hermann, C., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28996 · Cited by 133
Murakami, M., Ernsting, M. J., Undzys, E., Holwell, N., Foltz, W. D., & Li, S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0062 · Cited by 131
A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice
Fang, J., Liang, X., Joo, K., Liu, Y., Zhang, C., Liu, S., Conti, P. S., Li, Z., & Wang, P. (2015) · International Journal of Cancer · doi:10.1002/ijc.29831 · Cited by 129
Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more
Chiossone, L., Vienne, M., Kerdiles, Y. M., & Vivier, É. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.003 · Cited by 125
Sonic Hedgehog Signaling in Basal Cell Nevus Syndrome
Athar, M., Li, C., Kim, A. L., Spiegelman, V. S., & Bickers, D. R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1666 · Cited by 123
Geng, B., Pan, J., Zhao, T., Ji, J., Zhang, C., Che, Y., Yang, J., Shi, H. M., Li, J., Zhou, H., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0876-2 · Cited by 122
Li, T., Yi, S., Liu, W., Jia, C., Wang, G., Hua, X., Tai, Y., Zhang, Q., & Chen, G. (2013) · Medical Oncology · doi:10.1007/s12032-013-0663-z · Cited by 121
Park, Y. P., Choi, S., Kiesler, P., Gil-Krzewska, A. J., Borrego, F., Weck, J., Krzewski, K., & Coligan, J. E. (2011) · Blood · doi:10.1182/blood-2011-04-346825 · Cited by 121
Cancer-associated fibroblasts: key determinants of tumor immunity and immunotherapy
Barrett, R., & Puré, E. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.03.004 · Cited by 121
Kinoshita, T., Ishii, G., Hiraoka, N., Hirayama, S., Yamauchi, C., Aokage, K., Hishida, T., Yoshida, J., Nagai, K., & Ochiai, A. (2013) · Cancer Science · doi:10.1111/cas.12099 · Cited by 119
Shan, T., Chen, S., Chen, X., Lin, W. R., Li, W., Ma, J., Wu, T., Cui, X., Ji, H. L., Li, Y., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5479 · Cited by 119
The Role of Prostaglandin E 2 in Tumor-Associated Immunosuppression
Wang, D., & DuBois, R. N. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.11.003 · Cited by 118
Sow, H. S., Ren, J., Camps, M. G. M., OSSENDORP, F. A., & ten Dijke, P. (2019) · Cells · doi:10.3390/cells8040320 · Cited by 117
Libreros, S., Garcia‐Areas, R., & Iragavarapu‐Charyulu, V. (2013) · Immunologic Research · doi:10.1007/s12026-013-8459-y · Cited by 114
The Surprising Discovery That TGFβ Specifically Induces the IgA Class Switch
Stavnezer, J., & Kang, J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.5 · Cited by 114
Functional subsets of mesenchymal cell types in the tumor microenvironment
Cortez, E., Roswall, P., & Pietras, K. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.010 · Cited by 112
The roles of the COX2/PGE2/EP axis in therapeutic resistance
Tong, D., Liu, Q., Wang, L.-A., Xie, Q., Pang, J., Huang, Y., Wang, L., Liu, G., Zhang, D., Lan, W., et al. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9752-y · Cited by 111
Liu, L., Liu, L., Yao, H. H., Zhu, Z., Ning, Z. L., & Huang, Q. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159947 · Cited by 110
Bai, Y., Shang, K., Chen, H., Ding, F., Wang, Z., Liang, C., Xu, Y., Sun, M., & LI, Y. (2015) · Cancer Science · doi:10.1111/cas.12745 · Cited by 109
Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma
Wang, H., Chan, L., & Cho, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01084 · Cited by 109
Kovacs, R. J., Maldonado, G., Azaro, A., Fernández, M. S., Romero, F. L., Sepulveda-Sánchez, J. M., Corretti, M., Carducci, M., Dolan, M., Gueorguieva, I., et al. (2015) · Cardiovascular Toxicology · doi:10.1007/s12012-014-9297-4 · Cited by 108
Modulation of Cancer-Specific Immune Responses by Amino Acid Degrading Enzymes
Timosenko, E., Hadjinicolaou, A. V., & Cerundolo, V. (2016) · Immunotherapy · doi:10.2217/imt-2016-0118 · Cited by 108
Cancer-associated fibroblasts correlate with poor prognosis in rectal cancer after chemoradiotherapy
Saigusa (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.906 · Cited by 107
CHI3L1 promotes tumor progression by activating TGF-β signaling pathway in hepatocellular carcinoma
Qiu, Q., Wang, L., Jin, S., Liu, G.-F., Liu, J., Ma, L., Mao, R., Ma, Y., Zhao, N., Chen, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33239-8 · Cited by 106
Cancer Associated Fibroblasts: Naughty Neighbors That Drive Ovarian Cancer Progression
Dasari, S., Fang, Y., & Mitra, A. K. (2018) · Cancers · doi:10.3390/cancers10110406 · Cited by 105
Yao, Y., Guo, Q., Cao, Y., Qiu, Y., Tan, R. X., Zhou, Y., Zhou, Y., & Lu, N. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0960-7 · Cited by 104
Karavitis, J., Hix, L. M., Shi, Y. H., Schultz, R. F., Khazaie, K., & Zhang, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046342 · Cited by 98
Stretching Fibroblasts Remodels Fibronectin and Alters Cancer Cell Migration
Ao, M., Brewer, B. M., Yang, L., Franco Coronel, O. E., Hayward, S. W., Webb, D. J., & Li, D. (2015) · Scientific Reports · doi:10.1038/srep08334 · Cited by 96
Ohshio, Y., Teramoto, K., Hanaoka, J., Tezuka, N., Itoh, Y., Asai, T., Daigo, Y., & Ogasawara, K. (2014) · Cancer Science · doi:10.1111/cas.12584 · Cited by 95
Östman, A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.022 · Cited by 95
CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients
Lefort, S., Thuleau, A., Kieffer, Y., Sirven, P., Bièche, I., Marangoni, E., Vincent‐Salomon, A., & Mechta‐Grigoriou, F. (2016) · Oncogene · doi:10.1038/onc.2016.284 · Cited by 94
Self-citationLi, A., Chen, P., Leng, Y., & Kang, J. (2018) · Oncogene · doi:10.1038/s41388-018-0379-9 · Cited by 92
Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions
Joshi, S. (2020) · Cancers · doi:10.3390/cancers12082057 · Cited by 91
Arwert, E. N., Milford, E. L., Rullan, A., Derzsi, S., Hooper, S., Kato, T., Mansfield, D., Melcher, A., Harrington, K. J., & Sahai, E. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0527-7 · Cited by 90
Zhou, J., Wang, X.-H., Zhao, Y., Chen, C., Xu, X., Sun, Q., Wu, H., Chen, M., Sang, J., Su, L., et al. (2018) · Journal of Cancer · doi:10.7150/jca.28583 · Cited by 87
A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer
Bonneau, C., Eliès, A., Kieffer, Y., Bourachot, B., Ladoire, S., Pelon, F., Héquet, D., Guinebretière, J. M., Blanchet, C., Vincent‐Salomon, A., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01311-9 · Cited by 86
Self-citationMora‐García, M. D. L., García‐Rocha, R., Morales-Ramírez, O., Montesinos, J. J., Weiss‐Steider, B., Hernández‐Montes, J., Ávila-Ibarra, L. R., Don‐López, C. A., Velasco-Velázquez, M. A., Gutiérrez-Serrano, V., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1057-8 · Cited by 85
Strong, A. L., Pei, D. T., Hurst, C. G., Gimble, J. M., Burow, M. E., & Bunnell, B. A. (2017) · Stem Cells International · doi:10.1155/2017/9216502 · Cited by 84
Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: Ready for prime time?
Zucker, S., & Cao, J. P. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.24.10353 · Cited by 83
Gunderson, A. J., Yamazaki, T., McCarty, K., Phillips, M., Alice, A. F., Bambina, S., Zebertavage, L., Friedman, D. J., Cottam, B., Newell, P., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211117 · Cited by 79
Zhu, Y., Chen, S., Zeng, L., Liu, G., Jiang, W., Zhang, X., Chen, S., Guo, J., Jian, X., Ouyang, J., et al. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23150 · Cited by 78
What is natural in natural killer cells?
Vivier, É. (2006) · Immunology Letters · doi:10.1016/j.imlet.2006.07.004 · Cited by 77
Kock, A., Larsson, K., Bergqvist, F., Eißler, N., Elfman, L. H. M., Raouf, J., Korotkova, M., Johnsen, J. I., Jakobsson, P., & Kogner, P. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.05.008 · Cited by 77
Matrix metalloproteinase inhibitors as anticancer agents
Konstantinopoulos, P. A., Karamouzis, M. V., Papatsoris, A., & Papavassiliou, A. G. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.11.007 · Cited by 74
Miao, J., Xu, L., Hu, Y., Piao, C., Wu, X., Liu, X., Huang, C., Wang, Y., Li, D., & Liu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.21155 · Cited by 74
He, X., Tao, H., Hu, Z., Ma, Y., Xu, J., Wang, H., Xia, Y., Li, L., Fei, B., Li, Y., et al. (2014) · Cancer Science · doi:10.1111/cas.12539 · Cited by 73
Chiappori, A., Eckhardt, S., Bukowski, R. M., Sullivan, D. M., Ikeda, M., Yano, Y., Yamada‐Sawada, T., Kambayashi, Y., Tanaka, K., Javle, M. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1586 · Cited by 70
Inoue, T., Adachi, K., Kawana, K., Taguchi, A., Nagamatsu, T., Fujimoto, A., Tomio, K., Yamashita, A., Eguchi, S., Nishida, H., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3631 · Cited by 70
Zheng, X. M., Xu, M. M., Yao, B., Wang, C., Jia, Y., & Liu, Q. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.06.009 · Cited by 68
Genetic alterations and epigenetic alterations of cancer-associated fibroblasts
Du, H., & Che, G. (2016) · Oncology Letters · doi:10.3892/ol.2016.5451 · Cited by 66
Eichten, A., Su, J., Adler, A. P., Zhang, L., Ioffe, E., Parveen, A. A., Yancopoulos, G. D., Rudge, J. S., Lowy, I., Lin, H. C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1443 · Cited by 63
Trüb, M., Uhlenbrock, F., Claus, C., Herzig, P., Thelen, M., Karanikas, V., Bacac, M., Amann, M., Albrecht, R., Ferrara, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000238 · Cited by 63
Cancer-associated fibroblasts and macrophages: Friendly conspirators for malignancy
Chiarugi, P. (2013) · OncoImmunology · doi:10.4161/onci.25563 · Cited by 60
Yang, L., Han, S., & Sun, Y. J. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.09.129 · Cited by 60
miR-186 Regulates Glycolysis through Glut1 During the Formation of Cancer-associated Fibroblasts
Sun, P., Hu, J., Xiong, W., & Mi, J. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.10.4245 · Cited by 59
Sakamoto, A., Kunou, S., Shimada, K., Tsunoda, M., Aoki, T., Iriyama, C., Tomita, A., Nakamura, S., Hayakawa, F., & Kiyoi, H. (2018) · Cancer Science · doi:10.1111/cas.13873 · Cited by 57
Alcaraz, J., Carrasco, J. L., Millares, L., Luis, I.-C., Fernández-Porras, F. J., Martínez-Romero, A., Díaz‐Valdivia, N., de Cos, J. S., Rami–Porta, R., Seijo, L. M., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.07.020 · Cited by 55
Moatassim-Billah, S., Duluc, C., Samain, R., Jean, C., Perraud, A., Decaup, E., Cassant‐Sourdy, S., Bakri, Y., Sèlves, J., SCHMID, H. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9296 · Cited by 48
Epigenetic changes in fibroblasts drive cancer metabolism and differentiation
Mishra, R., Haldar, S., Suchanti, S., & Bhowmick, N. A. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0347 · Cited by 48
Ouyang, W., Oh, S. A., Ma, Q., Bivona, M. R., Zhu, J., & Li, M. O. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.016 · Cited by 45
IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells
Notarangelo, T., Sisinni, L., Trino, S., Calice, G., Simeon, V., & Landriscina, M. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.038 · Cited by 41
Chitinase 3 like 1 is associated with tumor angiogenesis in cervical cancer
Ngernyuang, N., Francescone, R., Jearanaikoon, P., Daduang, J., Supoken, A., Yan, W., Shao, R., & Limpaiboon, T. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.03.021 · Cited by 40
Wang, X., Cai, C., Xu, J.-M., Jin, H. D., & Xu, Z. (2014) · Tumor Biology · doi:10.1007/s13277-014-2690-6 · Cited by 34
Wang, J., Sheng, Z., Yang, W., & Cai, Y. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000438643 · Cited by 27
Melero, I., Álvarez, E. C., Mau‐Sørensen, M., Lassen, U., Lolkema, M. P., Robbrecht, D. G. J., Gomez‐Roca, C., Martín-Liberal, J., Tabernero, J. M., Ros, W., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy279.400 · Cited by 19
Cited by
Clinical and therapeutic relevance of cancer-associated fibroblasts
Chen, Y., McAndrews, K. M., & Kalluri, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00546-5 · Cited by 1,230
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Albelda, S. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00832-4 · Cited by 517
Jenkins, L., Jungwirth, U., Avgustinova, A., Iravani, M., Mills, A., Haider, S., Harper, J., & Isacke, C. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4141 · Cited by 279
Hirz, T., Mei, S., Sarkar, H., Kfoury, Y., Wu, S., Verhoeven, B. M., Subtelny, A. O., Zlatev, D. V., Wszolek, M. W., Salari, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36325-2 · Cited by 277
Metadata
- Authors
- Mhaidly, R., & Mechta-Grigoriou, F.
- Venue
- Seminars in Immunology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 48
- Pages
- 101417
- ISSN
- 1044-5323 (ISSN-L)
- OpenAlex
- W3093192089
- Cited by
- 259
- References
- 288
- FWCI
- 10.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.